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Abstract
Paramyxoviruses have been shown to produce proteins that inhibit interferon production and signaling. For human respiratory syncytial virus
(RSV), the nonstructural NS1 and NS2 proteins have been shown to have interferon antagonist activity through an unknown mechanism. To
understand further the functions of NS1 and NS2, we generated recombinant RSV in which both NS1 and NS2 were replaced by the PIV5 V
protein, which has well-characterized IFN antagonist activities (ΔNS1/2-V). Expression of V was able to partially inhibit IFN responses in ΔNS1/
2-V-infected cells. In addition, the replication kinetics of ΔNS1/2-V were intermediate between ΔNS1/2 and wild-type (rA2) in A549 cells.
However, expression of V did not affect the ability of ΔNS1/2-V to activate IRF3 nuclear translocation and IFNβ transcription. These data
indicate that V was able to replace some of the IFN inhibitory functions of the RSV NS1 and NS2 proteins, but also that NS1 and NS2 have
functions in viral replication beyond IFN antagonism.
© 2007 Elsevier Inc. All rights reserved.Keywords: Paramyxovirus; Interferon antagonism; NonstructuralIntroduction
Respiratory syncytial virus (RSV) is the most important
etiologic agent of pediatric viral respiratory infection and
remains a major cause of morbidity and mortality among infants
as well as immunocompromised subjects and the elderly
(Collins et al., 2001). RSV is classified in the family Para-
myxoviridae in the order Mononegavirales and is the prototype
member of the Pneumovirus genus. The nonsegmented,
negative-sense (NNS) RNA genome of RSV is 15,222 nt long
and contains 10 transcription units from which 11 proteins are
translated. A number of these proteins are homologous to
proteins from other paramyxoviruses, including nucleocapsid
(N nucleocapsid, P phosphoprotein, L polymerase), assembly
(M matrix), and attachment and fusion (G and F) proteins. In
addition, RSV encodes two proteins in the M2 gene (M2-1 and
M2-2) that are thought to play a role in regulating RNA
synthesis by the RSV polymerase complex. Finally, the NS1⁎ Corresponding author. Fax: +1 814 863 7024.
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doi:10.1016/j.virol.2007.06.017and NS2 proteins are nonstructural proteins which are
dispensable for viral replication in vitro; however, deletion of
either NS gene attenuates recombinant RSV (rRSV) signifi-
cantly in vitro and markedly in vivo (Buchholz et al., 1999; Jin
et al., 2000; Schlender et al., 2000; Teng and Collins, 1999;
Whitehead et al., 1999). RSV enters cells by direct fusion of its
envelope with the plasma membrane and replicates solely in the
cytoplasm. Transcription of the genome by the viral RNA-
dependent RNA polymerase is polar, such that the genes located
proximal to the genomic promoter at the 3′ end of the viral RNA
are transcribed earlier and to a greater extent than the promoter
distal genes. Production of viral proteins leads to assembly of
replicated genomes into encapsidated ribonucleoprotein (RNP)
complexes that traffic to the plasma membrane where virion
morphogenesis occurs. The primary site of infection is the
respiratory epithelium, with infection and release occurring at
the apical surface. A distinctive characteristic of RSV is that it
does not induce long-lived immunity upon exposure, resulting
in recurrent infection throughout life.
That viruses have developed mechanisms for inhibiting
antiviral activities induced by IFNs has been well documented.
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parainfluenza virus 5 (PIV5), formerly SV5, V protein. PIV5 is
a member of the Rubulavirinae genus of the family Paramyx-
oviridae (Lamb and Kolakofsky, 2001). The V protein of PIV5
is encoded by the V/P gene whose mRNA is “edited” during
transcription, resulting in the insertion of 2 G residues which
alters the reading frame and allows the production of the P
protein, an essential cofactor for the viral polymerase (Lamb
and Kolakofsky, 2001). PIV5 V shares its N-terminus with P,
but encodes a cysteine-rich C-terminus, which is well conserved
among paramyxoviruses, and is produced in relatively equimo-
lar amounts to P (Lamb and Kolakofsky, 2001). V has been
shown to assemble ubiquitin ligase complexes targeted to
STAT1, resulting in the proteasome-mediated degradation of
STAT1 (Ulane and Horvath, 2002). The polyubiquitylation of
STAT1 by these V-dependent ubiquitin ligase machines requires
species-specific recognition of STAT2 (Parisien et al., 2002). A
number of other paramyxoviruses have also been shown to
encode accessory proteins that target the JAK-STAT pathway to
inhibit IFN signaling (Andrejeva et al., 2002b; Didcock et al.,
1999; Horvath, 2004; Rodriguez et al., 2004; Young et al.,
2000). In addition to inhibiting IFN signaling, PIV5 V can
inhibit IFN production (He et al., 2002; Poole et al., 2002).
Recently, Andrejeva et al. have shown that this inhibition results
from the interaction of V with the DExD/H-box helicase MDA-
5 and blocks the activation of the transcription factors IRF3 and
NFκB (Poole et al., 2002). Other viruses have been shown to
inhibit IFN production, though the mechanisms by which this
effect occurs are not well described. One notable exception is
hepatitis C virus NS3/4A, which has been found to disrupt
IFN production by cleaving signal transduction proteins in
both the RIG-I and TLR3 pathways (Foy et al., 2005; Li et al.,
2005).
The nonstructural proteins of RSV also appear to have IFN
inhibitory functions. NS1 and NS2 are encoded by the two
promoter-proximal transcription units, making them the earliest
and most abundantly transcribed genes. These small proteins
(NS1, 139 aa; NS2, 124 aa) have no significant sequence
homology with each other or with any cellular protein in the
database. NS1 and NS2 appear to antagonize both the cellular
antiviral response as well as the induction of IFN production
(Bossert and Conzelmann, 2002; Bossert et al., 2003; Schlender
et al., 2000; Spann et al., 2004). This antagonism likely requires
the accumulation of NS1 and NS2 in the cell since RSV induces
STAT1 phosphorylation at early time points post-infection
(Kong et al., 2003); however, the mechanism for this
antagonism is unclear. Later in infection, RSV appears to
cause the degradation of STAT2, though this effect may be cell-
type-dependent (Ramaswamy et al., 2004). Recent evidence
suggests that both NS1 and NS2 are important for STAT2
degradation by RSV (Lo et al., 2005; Ramaswamy et al., 2006).
Thus, the attenuation of rRSV lacking NS1 and/or NS2 may be
due in part to the lack of interferon antagonism by these viruses.
However, even in interferon-deficient cells, the growth of rRSV
lacking NS1 and/or NS2 is attenuated (Jin et al., 2000; Spann et
al., 2004). Thus, the NS genes likely have functions required for
optimal RSV replication in addition to IFN antagonism. There issome evidence that NS1 may interact with viral proteins M and
P (Evans et al., 1996; Hengst and Kiefer, 2000) and expression
of NS1 in a minireplicon system strongly inhibits RNA
replication and transcription by the RSV polymerase, though
the mechanism is unknown (Atreya et al., 1998). Therefore,
these small nonstructural proteins encode multiple functions
that are essential for optimal RSV replication.
Results
Recovery of rRSV containing the V gene of PIV5 in place of the
NS1 and NS2 genes of RSV
Recent studies have implicated NS1 and NS2 in antagoniz-
ing the host interferon response in RSV-infected cells (Bossert
et al., 2003; Spann et al., 2004, 2005). As an initial step in
determining the mechanism of this interferon antagonism, we
replaced the NS1 and NS2 with the open reading frame of the
PIV5 V gene (Fig. 1a). Since the V mRNA can be “edited”
during PIV5 infection, resulting in the insertion of 2 G residues,
we cloned in two versions of the V ORF. The first contained the
wild-type V ORF (Vwt) and the second contained a V ORF in
which the editing site was mutated to prevent insertion of G
residues (Vmut). Both rRSVs encoding V in place of NS1 and
NS2 (ΔNS1/2-Vwt or ΔNS1/2-Vmut) were recovered essen-
tially as described (Buchholz et al., 1999).
We next examined if the mutant rRSVs expressed the proper
complement of viral proteins. Therefore, we performed Western
blot analysis of whole cell lysates derived from Vero cells
infected by rA2,ΔNS1/2,ΔNS1/2-Vwt, orΔNS1/2-Vmut (Fig.
1b). As expected, these viruses all expressed the RSV structural
proteins and the ΔNS1/2 derivatives did not express either
nonstructural protein. In addition, the V mutant rRSVs
expressed immunoreactive V protein that migrates at the same
rate with PIV5 V in SDS-PAGE (Fig. 1b, middle panel).
We constructed two versions of the V mutant rRSVs since it
was formally possible that the RSV polymerase could recognize
the PIV5 editing site and insert two Gs during transcription,
altering the coding frame, and thus the protein sequence, of the
C-terminus of V. The antibody used in the Western blot only
recognizes the common N-terminus of the PIV5 P and V
proteins, so V protein derived from edited or unedited mRNAs
would be recognized similarly. V from edited mRNA in the
ΔNS1/2-Vwt-infected cells would be predicted to be 13
residues longer, though the amino acid composition of the C-
terminus would be completely different. We were unable to
detect a difference in electrophoretic mobility between V
expressed from PIV5 compared with that from either rRSV by
Western blot (Fig. 1b). However, to ensure that no editing had
occurred, we isolated total RNA from PIV5, ΔNS1/2-Vwt, and
ΔNS1/2-Vmut-infected cells, amplified the V mRNA by PCR
using specific primers, and sequenced the resulting PCR
fragment. As expected, the sequence of V mRNA derived
from PIV5-infected cells becomes heterogeneous after the
editing site, indicative of the insertion of G residues. However,
PCR fragments derived from the V mutant rRSV showed
homogeneous sequences throughout this region regardless of
Fig. 1. Generation of V mutant rRSV. (a) Genomic structure of V mutant rRSV. (b) Expression of viral proteins in rRSV-infected cells. Vero cells were infected by the
indicated viruses at an MOI of 3. Cell lysates were harvested at 16 h p.i. and separated by SDS-PAGE. Viral proteins were detected by Western blot analysis using
antibodies directed against RSV structural proteins (top), V (middle), or NS1 and NS2 (bottom). (c) Electropherograms of sequences of Vediting sites. Total RNAwas
extracted from cells infected by PIV5,ΔNS1/2-Vwt, andΔNS1/2-Vmut at an MOI of 3 for 16 h and subjected to RT-PCR using the V cloning primers. PCR fragments
were isolated and sequenced.
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polymerase does not recognize the V editing site.
PIV5 V has previously been shown to be responsible for both
inhibition of MDA-5 and STAT1 degradation, leading to
antagonism of both IFNβ production and signaling, respec-
tively (Andrejeva et al., 2002a, 2004; Didcock et al., 1999; He
et al., 2002). Therefore, we sought to show that the Vexpressed
by the mutant rRSVs was functional by assessing the status ofFig. 2. V expressed by rRSV causes STAT1 degradation. A549 cells were infected b
Total cell extracts were harvested at 4-h intervals as indicated and subjected to West
control for infection.STAT1 in infected cells by Western blot. A549 cells were
infected by rA2,ΔNS1/2,ΔNS1/2-Vwt, orΔNS1/2-Vmut at an
MOI of 3 and samples were harvested at 4-h intervals post-
infection (p.i.). The accumulation of V, STAT1, and N (infection
control) protein was detected by Western blot (Fig. 2). The
expression of STAT1 decreased slightly over time in rA2-
infected cells, but was detectable even 36 h p.i. (Fig. 2a). In
contrast, STAT1 levels increased markedly during the course ofy rA2 (a), ΔNS1/2 (b), ΔNS1/2-Vmut (c), or ΔNS1/2-Vwt (d) at an MOI of 3.
ern blot analysis using antibodies to V and STAT1. N expression is shown as a
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ΔNS1/2-Vwt-infected cells, STAT1 levels decreased to unde-
tectable levels by 20 h p.i. (Figs. 2c and d). Interestingly,
accumulation of detectable V did not occur until 20–24 h p.i. in
V mutant rRSV-infected cells. Thus, depression of STAT1
occurred in infected cells with undetectable levels of V.
Regardless, the expression of V by the mutant rRSVs was
sufficient to completely knock out the presence of STAT1 in
infected cells, indicating that the expressed V is functional.
PIV5 V partially rescues the interferon antagonism of RSV NS1
and NS2
Since NS1 and NS2 have been shown to have interferon
antagonist activity, we next examined whether PIV5 V could
inhibit IFN production and signaling in the context of RSV
infection. Therefore, we examined the level of IFNβ mRNA in
cells infected by the V mutant rRSVs. Total cellular RNA was
isolated from infected A549 cells at 16 h p.i. and was subjected
to Northern blot analysis using a radiolabeled probe for IFNβ
(Fig. 3). Infection by rA2 results in barely detectable
accumulation of IFNβ mRNA after 16 h p.i., while ΔNS1/2-
infected cells contain elevated amounts of IFNβ mRNA (Fig.
3). Interestingly, infection by the V mutant rRSVs resulted in an
intermediate level of IFNβmRNA accumulation. Densitometric
analysis indicated that IFNβ mRNA levels were approximately
2-fold greater in V mutant rRSV versus rA2-infected cells,
while ΔNS1/2-infected cells contained N6-fold higher levels.
Thus, V expression was partially effective in replacing the
inhibition of IFNβ production by NS1 and NS2.
We next examined the transcription of the ISG15 gene, which
can be activated both by interferon signaling through the JAK/
STAT pathway as well as by IRF3. Infection by rA2 resulted in a
low level of ISG15 mRNA accumulation, consistent with the
low IFNβ levels, while ΔNS1/2 infection induced higher levels
(Fig. 3). As expected, ISG15 mRNA in V mutant rRSV-infected
cells was expressed at similarly low levels as those in rA2-
infected cells. These levels were approximately 2-fold lower
than those in ΔNS1/2-infected cells by densitometry. TheseFig. 3. Accumulation of IFNβ and ISG15 mRNA in rRSV-infected cells. A549
cells were infected with the indicated viruses at an MOI of 3. At 8, 12, and 16 h
p.i., total RNA was isolated from the infected cells and subjected to Northern
blot analysis using radiolabeled DNA probes to IFNβ (top) or ISG15 (bottom).
Bands were visualized by autoradiography. After exposure, the blots were
stripped and reprobed with a radiolabeled probe for GAPDH as a loading control
(lower panels).data suggest that V, like NS1/2, is able to inhibit JAK/STAT
signaling in the context of RSV infection, albeit using a
different mechanism.
Transcription from the IFNβ promoter requires the activation
and nuclear translocation of IRF3. Previous studies have shown
that infection of cells with RSV lacking NS1 and/or NS2
induces activation of IRF3 (Bossert et al., 2003; Spann et al.,
2005). Therefore, we examined the subcellular localization of
IRF3 in RSV-infected cells. A549 cells were infected by rA2,
ΔNS1/2, or the V mutant rRSVs and subjected to immuno-
fluorescence assays using antibodies to RSV F and IRF3. The
percentages of infected cells with nuclear IRF3 were determined
at 9, 12, and 16 h p.i. (Figs. 4a–c). At early time points after
infection, IRF3 nuclear translocation was not significantly
different among the infected cell populations (Figs. 4a and b);
however, by 16 h p.i.,ΔNS1/2-infected cells had approximately
twice as many cells with nuclear IRF3 compared with rA2 (Fig.
4c). A549 cells infected by ΔNS1/2-Vmut or ΔNS1/2-Vwt
behaved similarly to those infected byΔNS1/2, showing∼70%
of the cells having nuclear IRF3 at 16 h p.i. (Fig. 4c). To confirm
that the nuclear localization of IRF3 was indicative of its
activation, we performed a Western blot analysis for phos-
phorylated IRF3 (Fig. 4d). Consistent with the immunofluor-
escence analysis, cells infected by ΔNS1/2 or the V mutant
rRSVs showed similar levels of Ser396 phosphorylation. In
addition, we performed an electrophoretic mobility shift assay
(EMSA) using oligonucleotide probes for the interferon-
stimulated response element (ISRE) from the ISG15 gene
(Fig. 4e). We found that nuclear extracts from rRSV-infected
A549 cells formed complexes that specifically retarded the
mobility of the probe and that this binding could be ablated by
incubation with excess cold competitor. Thus, in contrast to the
Northern blot results with IFNβ, expression of V did not alter
the ability of ΔNS1/2 to induce IRF3 activation.
PIV5 V does not rescue the viral replication of ΔNS1/2
Previous studies with rRSV lacking NS1 and NS2 indicated
that these viruses display decreased plaque size and growth
kinetics in cell culture (Jin et al., 2000; Spann et al., 2004).
Therefore, we examined multiple-step replication of the V
mutant rRSVs in a number of cell lines. Growth ofΔNS1/2 was
significantly decreased in human (A549, HEp-2, HeLa) and
monkey (Vero) cell lines compared with rA2 (Fig. 5).
Replication of the V mutant rRSVs was intermediate between
rA2 and ΔNS1/2 in A549 cells (Fig. 5a), mirroring the partial
inhibition of IFN seen above. However, replication of the V
mutant rRSVs was similar to that of ΔNS1/2 in IFN-deficient
Vero cells (Fig. 5b). Interestingly, ΔNS1/2 and the ΔNS1/2-V
mutants displayed similar growth kinetics in HEp-2 and HeLa
cell (Figs. 5c and d). Also, V mutant rRSVs formed plaques
with similar decreased size and morphology as ΔNS1/2 in both
HEp-2 and Vero cells, reflecting the multiple step replication
results (data not shown). Plaque formation by any of the rRSV
was not detectable in A549 or HeLa cells (data not shown).
Therefore, expression of V cannot replace the functions of NS1
and NS2 in viral replication beyond IFN antagonism.
Fig. 4. Activation of IRF-3 in rRSV-infected cells. A549 cells on coverslips were infected at an MOI of 3 by the indicated viruses. At 9 (a), 12 (b), or 16 (c) h p.i.,
coverslips were fixed in formalin, permeabilized, and subjected to indirect immunofluorescence using antibodies to F (green) and IRF-3 (red). The percentages of
infected cell displaying nuclear IRF-3 (graphs) were determined by counting approximately 300 cells per coverslip. Each sample was assayed in triplicate. Error bars
represent SEM. (d) A549 cells were infected at an MOI of 3 by the indicated viruses. Total cell lysates were harvested 16 h p.i. and subjected to Western blot analysis
for phosphorylated (Ser396) and total IRF3. (e) EMSA for IRF3 binding. A549 cells were infected at an MOI of 3 by the indicated viruses. Nuclear extracts were
harvested at 16 h p.i. and used in an EMSA with a radiolabeled ISRE probe. CC, 100× cold competitor.
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by the PIV5 polymerase (Lin et al., 2005). To determine
whether expression of V altered the function of the RSV
polymerase, we performed Northern blot analysis examining
the production of viral RNAs in rRSV-infected cells. N mRNA
accumulated over time to a similar extent in HEp-2 cells
infected by rA2, ΔNS1/2, ΔNS1/2-Vwt, or ΔNS1/2-Vmut
(Fig. 6). In addition, the expected patterns of readthrough
mRNAs were present, including the novel V-N dicistronic
mRNA in the ΔNS1/2-V-infected cells. As expected, genome
length RNA (Fig. 6, G/AG) accumulated dramatically over
time in rA2-infected cells but poorly in ΔNS1/2-infected cells.
Accumulation of these RNA species in ΔNS1/2-V-infected
cells was similar to that seen with ΔNS1/2 (Figs. 6c and d).Thus, V does not appear to affect the function of the RSV
polymerase.
Discussion
We have shown that RSV encoding the PIV5 V protein in
place of NS1 and NS2 is viable and express functional V. Our V
mutant rRSVs encode the V gene at the promoter proximal
position in the gene order. Therefore, V should be highly
expressed in ΔNS1/2-V-infected cells. However, PIV5 appears
to produce significantly more V protein during infection than
does ΔNS1/2-Vwt or ΔNS1/2-Vmut. Whether this differential
regulation occurs at the level of transcription or translation is
currently unknown. In PIV5-infected cells, the viral polymerase
Fig. 5. Multiple step growth analysis of V mutant rRSV. A549 (a), Vero (b), HEp-2 (c), or HeLa (d) cells were infected with the V mutant rRSVat an MOI of 0.01 and
supernatant samples were harvested daily for 5 days p.i. Supernatants were clarified and viral titers were determined. The analysis was performed in triplicate. Shown
are the mean titers; error bars represent the SEM.
Fig. 6. Viral RNA production in rRSV-infected cells. HEp-2 cells were infected
by rA2 (a), ΔNS1/2 (b), ΔNS1/2-Vmut (c), or ΔNS1/2-Vwt (d) at an MOI of 3.
Total cellular RNAwas harvested at 4-h intervals as indicated and subjected to
Northern blot analysis using a radiolabeled DNA probe to RSV N. Viral RNA
species are indicated on the right. G/AG, genome/antigenome.
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transcription. This process (mRNA “editing”) results in the
production of the P mRNAwhose product is essential for viral
replication. Since paramyxovirus polymerases are thought to
operate by similar mechanisms, we replaced NS1 and NS2 in
rRSV with either the wild-type V gene or a mutant V that cannot
be edited, to ensure that V would be properly expressed.
However, we found that the RSV polymerase does not insert G
residues into the wild-type V mRNA containing the editing site.
Since editing sequences among the paramyxoviruses are highly
homologous, our results suggest that the lack of editing of RSV
mRNAs is likely due to differences in polymerase function
rather than the absence of editing signals.
Recently, a great deal of attention has been focused on the
interferon antagonist properties of paramyxovirus accessory
proteins, of which PIV5 V is the best studied example. Inhibition
of IRF-3 activation and STAT1 degradation by V both require
the unique C-terminus of the protein, though the exact residues
responsible for these effects are unknown (Andrejeva et al.,
2002a; He et al., 2002). RSV NS1 and NS2 have also been
shown to inhibit IFN production and signaling (Bossert et al.,
2003; Spann et al., 2004; Spann et al., 2005). Therefore, we
investigated whether the IFN antagonism of V could function-
ally replace that of NS1 and NS2. The Vexpressed by rRSV was
functional in terms of STAT1 degradation, indicating the
presence of an intact V protein. Expression of V in place of
NS1 and NS2 appeared to partially inhibit IFNβ mRNA
accumulation in A549 cells. However, there was no apparent
difference in the percentage of infected cells with nuclear IRF3
in A549 cells infected byΔNS1/2 orΔNS1/2-V, nor was there a
significant difference in the Ser396 phosphorylation and ISRE
binding of IRF3 in these cells. The reasons for this discrepancy
are not clear. It is known that activation of IFNβ transcription is
Table 1
Oligonucleotides used for cloning
Primer name Sequence
NS1 ATG NheI R CAATGAATTGCTAGCATCTCTAACC
NS2 TAA BsiWI F TAATCCACGTACGTAAATTTCAACACAATA
PIV5 V F TTTGCTAGCGATCCCACTGATCTGAGCTTCTCCCC
PIV5 V R CGGCGTACGTTAAGTATCTCGTTCACATTCAGAGC
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induced NFκB expression, leading to decreased accumulation of
IFNβ mRNA. Alternatively, IFNβ production is thought to
activate a positive feedback loop involving IRF7, which has
been shown to be a master regulator for type I interferon
responses (Honda et al., 2005). This feedback loop would be
interrupted in cells in which the JAK/STAT pathway has been
inhibited (e.g., NS1/2- or V-expressing cells), resulting in
reduced expression of IFNβ. ISG15 transcription, which is
induced by IFN, was relatively equal in rA2 and ΔNS1/2-V-
infected cells, suggesting that JAK/STAT signal transduction
abrogated in these cells, in contrast to the increased levels seen
with ΔNS1/2 infection. Thus, V was able to partially, but not
fully, complement the IFN inhibitory effects of NS1 and NS2.
It is possible that V does not encode the full spectrum of IFN
antagonist activities of NS1 and NS2. NS1 and NS2 have been
shown to target STAT2 for degradation (Lo et al., 2005;
Ramaswamy et al., 2006), but other activities for NS1 and NS2
have not been described. Also, it is possible that NS1 and NS2
act in tandem to subvert multiple IFN activation pathways.
Thus, the IFN antagonism of either NS1 or NS2 alone may be
able to be replaced by V. In this light, it is interesting to note that
rRSV lacking NS1 (ΔNS1) or NS2 (ΔNS2) replicates more
efficiently in cells that constitutively express V compared to
non-expressing control cells (Young et al., 2003). However,
wild-type rA2 as well as rRSV lacking SH or G also replicates
to higher levels in V-expressing HEp-2 and 2fTGH cells
compared to control, suggesting that the effect of V is not
strictly related to its IFN antagonism.
Since expression of V by PIV5 inhibits IFN induction, our
data suggest that PIV5 and RSV may activate IFN transcription
by overlapping but distinct pathways. PIV5 V binds and inhibits
the DEXD/H box helicase MDA-5 (Andrejeva et al., 2004).
However, accumulation of detectable levels of V protein in V
mutant rRSV-infected cells does not occur until later in
infection. Thus, our results do not exclude the possibility that
MDA-5 is involved in IFN induction by RSV. Given the
sustained increase in IRF3 activation in V mutant rRSV-infected
cells, it is likely that other molecules play more important roles
in IFN induction. Other pathways that are activated by RNA
virus infection include a related DEXD/H box helicase, RIG-I,
and TLR3 (Conzelmann, 2005). Recent studies by us and others
indicate that RIG-I and TLR3 are essential for IFN induction by
RSV (Liu et al., 2007). We are currently determining the relative
contribution of each of these pathways to RSV-induced IFN
activation.
In addition to their IFN antagonist activities, NS1 and NS2
appear to play a role in viral replication. Accordingly, the plaque
morphology and multiple step growth characteristics of ΔNS1/
2-Vwt and ΔNS1/2-Vmut are similar to that of ΔNS1/2,
markedly decreased compared to wild-type rA2. This growth
deficiency appears to be partially relieved by V in A549 cells,
but not HEp-2 or HeLa cells. The reason for this cell-line-
specific effect is not known. It is possible that RSV replication is
more sensitive to IFN in A549 cells compared to the other cell
lines and the partial IFN inhibition due to V is sufficient to allow
enhanced viral growth. In addition, A549 cells are derived fromhuman lung carcinoma and may more closely resemble lung
epithelial cells than HEp-2 (larynx carcinoma) or HeLa
(cervical carcinoma) cells.
Even in IFN-deficient Vero cells, the ΔNS1/2-V mutants
replicated similarly to ΔNS1/2, indicating that NS1 and/or NS2
perform functions important for viral replication unrelated to
their IFN antagonist activities. NS1 has been previously shown
to regulate RNA synthesis by the RSV polymerase in a
minigenome system (Atreya et al., 1998). In addition, we have
observed that accumulation of RSV N mRNA is slower in cells
infected by ΔNS1 or ΔNS1/2 compared to rA2 over the course
of a single round of replication (K.C.T. andM.N.T., unpublished
data). Thus, NS1 may regulate RSV replication at the level of
RNA synthesis. NS2 does not appear to affect RSV macro-
molecule synthesis. However, deletion ofNS2 from recombinant
RSV results in pinpoint plaque formation (Teng and Collins,
1999), indicating that NS2 may regulate cell–cell fusion, either
by directly affecting F or altering cellular functions.
Deletion of either NS1 or NS2 results in viruses that are
extremely attenuated in chimpanzees while inducing protective
immunity against subsequent RSV challenge, indicating that
these mutant RSVs may be good vaccine candidates (Jin et al.,
2000; Teng et al., 2000; Whitehead et al., 1999). Indeed, initial
studies in human volunteers with NS2-deleted viruses show
promising safety and immunogenicity (Wright et al., 2006).
Therefore, understanding the mechanisms by which NS1 and
NS2 affect viral replication may enhance our ability to engineer
effective vaccines and design antiviral therapies for RSV.
Materials and methods
Plasmid construction
To replace, the NS1 and NS2 ORFs of RSV with PIV5 V,
unique restriction sites were engineered into pGEM-NS (Teng
and Collins, 1999) by inverse PCR mutagenesis using
DeepVent DNA polymerase (NEB). A NheI site was generated
downstream of the translation initiation codon of NS1 and a
BsiWI site was inserted upstream of the NS2 translation
termination codon using the phosphorylated primers NS1 ATG
NheI R and NS2 TAA BsiWI F (Table 1). PIV5 V containing a
functional editing site (Vwt) or a mutant editing site (Vmut) was
amplified from pBH360 and pBH361, respectively, using
primers PIV5 V F and PIV5 V R, which encode NheI and
BsiWI restriction sites, respectively. The V ORFs were cloned
into pGEM-NS using the engineered sites and sequenced. The
fragments for each mutant were introduced back into the
antigenome cDNA for RSV, resulting in D53ΔNS1/2-Vwt and
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nant RSV.
Recovery of recombinant RSV
Recovery of recombinant RSV from cloned DNA was
performed as described previously (Collins et al., 1995).
Briefly, monolayers of BSR-T7 cells in 6-well plates were
transfected using GeneJuice (Novagen) with a mixture of
plasmids encoding the RSV N, P, L, and M2-1 proteins and
either wild-type or mutant antigenome cDNA (1, 1, 0.5, 0.5, and
1 μg each/well). The transfection mixture was removed after
20 h of incubation at 37 °C and replaced with fresh medium
(DMEM supplemented with 5% fetal bovine serum, Life
Technologies). After an additional 48 h, the supernatants were
harvested, clarified by centrifugation, and passaged onto fresh
Vero cells. The recovered viruses were harvested 4 days later.
Viral titers were determined by plaque assay on Vero cells.
Plaques were visualized by immunostaining using a cocktail of
three murine anti-F monoclonal antibodies followed by horse-
radish peroxidase-coupled anti-mouse IgG antibodies and 4CN
substrate (Kirkegaard and Perry Laboratories) as described
(Murphy et al., 1990). The presence of the expected mutations
was confirmed in recombinant virus by RT-PCR of viral
genomic RNA and nucleotide sequencing.
Northern blot and Western blot analysis
A549, Vero and HEp-2 cells were infected in three
independent experiments with wild-type or V mutant viruses
at a multiplicity of infection (MOI) of 3 PFU per cell. In each
experiment, an aliquot of each inoculum was analyzed by
plaque assay to confirm the titer. Cells were collected at 0, 4, 8,
12, 16, 20, 24 and 36 h post-infection and divided into two
aliquots: one was harvested to isolate total intracellular RNA
using TRIzol reagent (Invitrogen), and the other was processed
for protein analysis by the addition of 2× gel sample buffer (100
mM Tris–Cl pH 6.8, 4% SDS, 20% glycerol, 0.2% bromophe-
nol blue, 200 mM DTT) and centrifugation through Qiashred-
ders (Qiagen). RNA samples were subjected to electrophoresis
in 1.0% or 1.2% agarose gels containing formaldehyde,
transferred to nitrocellulose (Optitran, 0.2 μm; Schleicher and
Schuell), and hybridized with 32P-labeled double-stranded
DNA probes prepared by random hexamer labeling using the
Megaprime DNA Labeling Systems (Amersham Life Science).
For Western blot analysis, cell extracts were electrophoresed
through 10% (for STAT1 and RSV structural proteins) or 12%
(for V proteins) polyacrylamide Tris–glycine gels. Proteins
were transferred to nitrocellulose membrane (BioTrace NT,
Pall) then incubated with rabbit antibodies raised against
purified RSV virions (Bukreyev et al., 1997) or with
monoclonal antibodies specific to PIV5 V/P (Pk) or STAT1
(Santa Cruz). Bound antibodies were visualized by secondary
incubation with horseradish peroxidase-coupled goat anti-rabbit
IgG or goat anti-mouse IgG antibodies (Kirkegaard and Perry)
followed by chemiluminescence (Pierce). To detect IRF3,
proteins were transferred to Immobilon FL (Millipore) andincubated with anti-IRF3 (Santa Cruz) or anti-phospho-Ser396
IRF3 (Cell Signaling) per the manufacturer's directions. Bound
IRF3 antibodies were detected by alkaline phosphatase-coupled
secondary antibodies and chemifluorescence (ECF, Amersham)
followed by quantitation using a Typhoon phosphorimager
(Molecular Dynamics).
Growth of rRSV in vitro
Triplicate cell culture monolayers of A549, Vero, HEp-2, and
HeLa cells were infected with each of the V recombinant
viruses,ΔNS1/2 or rA2 at an MOI of 0.01 PFU per cell. In each
experiment, an aliquot of each inoculum was analyzed by
plaque assay to confirm the titer. Cell culture media from
infected cells were collected daily for 5 days and virus titers
were determined by plaque assay in the Vero cell. Plaques were
visualized by immunostaining as described above.
Immunofluorescence assay
A549 cells were plated on coverslips, incubated overnight at
37 °C, then infected by the different rRSV at an MOI of 3 in
triplicate. At 9, 12, and 16 h p.i., the cells were fixed in formalin
and permeabilized by the addition of 0.1% Triton X-100.
Subcellular localization of IRF3 was detected by staining with
rabbit anti-human IRF3 (Santa Cruz) followed by Cy3-coupled
goat anti-rabbit Ig (Jackson Immunologicals). Virus-infected
cells were detected by staining with anti-F monoclonal antibody
(MAb1269, Beeler and van Wyke Coelingh, 1989) followed by
Alexa488-coupled goat anti-mouse Ig (Jackson Immunologi-
cals). Percentages of infected cells showing nuclear localization
of IRF3 were determined by counting approximately 300
infected cells in 10 fields per coverslip. Each experimental time
point was performed in triplicate so that each percentage
represents between 900 and 1000 cells counted. Micrographs
were taken using a Zeiss Axioplan epifluorescence microscope
with a 63× Apochromat oil immersion objective.
Electrophoretic mobility shift assay (EMSA)
A549 cells were infected by rA2,ΔNS1/2,ΔNS1/2-Vmut or
ΔNS1/2-Vwt at MOI of 3. Sixteen hours (post-infection) p.i.,
cells were harvested, washed with ice-cold 1× PBS, then
resuspended in 10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM
EDTA, 0.1 mM EGTA, 1 mM dithiothreitol (DTT), and 0.5 mM
phenylmethylsulfonyl fluoride (PMSF). The suspension was
left on ice for 30 min and brought to a final concentration of
0.5% NP-40. Samples were vortexed for 10 s then spun for 30 s
at 16,000×g. Supernatants were removed and the pellets were
resuspended in 20 mM HEPES pH 7.9, 400 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1 mM DTT, and 0.5 mM PMSF. Samples
were mixed on a rotator at 4 °C for 15 min and spun at 16,000×g
for 5 min at 4 °C. Nuclear extracts were assayed for IRF3
binding in gel shift analysis using a 32P-labeled double-stranded
oligonucleotide corresponding to the ISRE of the ISG15 gene
(5′-GATCGGAAAGGGAAACCGAAACTGAAGCC-3′).
Complexes were formed by incubating the probe with 10 μg of
81K.C. Tran et al. / Virology 368 (2007) 73–82nuclear extract for 30 min at room temperature in 20 mM Tris–
Cl (pH 7.5), 100 mMNaCl, 5% glycerol, 2 mMMgCl2 and poly
(dI–dC) (3 μg). Extracts were run on a 6% polyacrylamide gel
prepared in 1× Tris/borate/EDTA (TBE) at 20 mA for 3 h.
Subsequently, the gel was dried and exposed to Kodak BioMax
film at −80 °C overnight.
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